系统性硬化症标准化诊疗:Mayo Clinic经验
中位随访23个月时2年总生存率为91.67%、无事件生存率为74.51%,皮肤病变显著改善且肺功能稳定,毒性可接受。
要点
- 严重SSc经标准免疫抑制治疗仍进展者,可考虑在多学科模式下实施autoHCT。
- 2年OS 91.67%、EFS 74.51%,2年复发累积发生率23.93%、NRM 8.33%。
- 感染并发症发生于56%的患者,以病毒再激活为主;早期转诊或可进一步降低复发与治疗相关并发症。
核心结论
- 在多学科诊疗模式下将autoHCT作为严重SSc的标准治疗策略,与良好的生存结局和有意义的皮肤病变改善相关,且毒性可接受。
- 作者认为更早转诊和优化预处理策略可能进一步降低复发率和治疗相关并发症。
研究设计与样本
- 入组要求为标准免疫抑制治疗下仍进展;主要终点为总生存(OS)和无事件生存(EFS),次要终点包括复发与非复发死亡(NRM)累积发生率、器官特异性结局和移植相关并发症。
- 共25例患者接受autoHCT,中位年龄46岁,80%为女性。
主要发现
- 中位随访23个月(四分位距16.4-31.9)时,2年OS为91.67%(95%CI 81.25-100.0),EFS为74.51%(95%CI 58.78-94.45)。
- 2年复发累积发生率为23.93%(95%CI 4.27-43.59),NRM为8.33%(95%CI 2.97-19.64)。
- 改良Rodnan皮肤评分(mRSS)在第+90天和第+180天显著改善(P<0.05),肺功能保持稳定。
- 感染并发症发生于56%的患者,以病毒再激活为主。
关键数值与推荐
- 2年OS 91.67%(95%CI 81.25-100.0),EFS 74.51%(95%CI 58.78-94.45)。
- 2年复发累积发生率23.93%(95%CI 4.27-43.59),NRM 8.33%(95%CI 2.97-19.64)。
- mRSS在第+90天和第+180天较基线显著改善(P<0.05)。
- 感染并发症发生率56%,以病毒再激活为主。
临床怎么用
- 对标准免疫抑制治疗下仍进展的严重SSc患者,可在多学科诊疗模式下评估并实施autoHCT。
- 移植后需重点监测感染,尤其是病毒再激活,并随访皮肤与肺功能变化。
- 作者建议更早转诊并优化预处理策略,以降低复发和治疗相关并发症。
局限性
- 为单中心回顾性分析,样本量仅25例,随访时间有限(中位23个月)。
- 未设对照组,无法与常规免疫抑制治疗进行直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is an autoimmune disease marked by immune dysregulation, leading to progressive fibrosis and multiorgan dysfunction. Autologous hematopoietic cell transplantation (autoHCT) has demonstrated superiority over conventional immunosuppression in randomized trials yet remains underused in the United States. We report outcomes following implementation of autoHCT as a standard-of-care strategy at our institution. METHODS: We performed a retrospective analysis of consecutive patients with severe SSc undergoing autoHCT between April 1, 2020, and December 31, 2023. Eligibility required progressive disease despite standard immunosuppressive therapy. Primary endpoints were overall survival (OS) and event free survival (EFS). Secondary endpoints included cumulative incidence of relapse and nonrelapse mortality (NRM), organ-specific outcomes, and transplant-related complications. RESULTS: Twenty-five patients underwent autoHCT. Median age was 46 years; 80% were female. At a median follow-up of 23 (interquartile range 16.4-31.9) months, two-year OS was 91.67% (95% confidence interval [CI] 81.25-100.0) and EFS was 74.51% (95% CI 58.78-94.45). Two-year cumulative incidence of relapse was 23.93% (95% CI 4.27 -43.59), and NRM was 8.33% (95% CI 2.97-19.64). Significant improvement in Modified Rodnan Skin Score was observed at day +90 and +180 (P < 0.05), whereas pulmonary function stabilized. Infectious complications occurred in 56% of patients, primarily viral reactivations. CONCLUSION: Implementation of autoHCT for severe SSc in a multidisciplinary care model was associated with favorable survival and meaningful improvement in skin disease, with acceptable toxicity. Earlier referral and optimization of conditioning strategies may further reduce relapse and treatment-related morbidity.
引用
- Ayala E, Iqbal M, Meier T, et al. Adopting a Standard of Care for Systemic Sclerosis: The Mayo Clinic Experience. Arthritis Care Res (Hoboken). 2026. PMID: 42533863. doi:10.1002/acr.80129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。